by marketing@seuss.plus | Mar 23, 2023 | Uncategorized
– ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells – Basel, March 23, 2023 – Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600... 
by admin | Mar 16, 2023 | Press Releases
– OMNIA-2 is a Phase I/II study evaluating ANV419 as monotherapy and in combination with daratumumab, or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma – Basel, March 16, 2023 – Anaveon, a clinical stage,... 
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual MeetingMarch 23, 2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myelomaMarch 16, 2023
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanomaFebruary 2, 2023